AVP and metabolic dysfunction-associated steatotic liver disease: The presence of significantly greater copeptin levels in obese+/NAFLD+ than both obese+/NAFLD− and obese−/NAFLD− was confirmed by the post hoc adjusted ANOVA test (model F = 4.09, p = 0.019; p = 0.022 and p = 0.034), whereas no statistically significant difference was observed between plasma copeptin in obese individuals without NAFLD and non-obese control subjects (Table 1).